[theold]

The study was conducted in Chile between June 27, 2021, and January 12, 2022. 

The authors have used a large prospective national cohort that included approximately two million children and adolescents.

More specifically, for children and adolescents that underwent a full primary immunization with CoronaVac, the adjusted vaccine effectiveness was 74.5%, 91.0%, and 93.8% for COVID-19 development, hospitalization, and ICU admission, respectively.

Literature shows certain benefits, as vaccination can prevent severe COVID-19 cases and potential deaths among children with underlying health conditions. 

Furthermore, the vaccination may prevent long-term consequences of SARS-CoV-2 infection, including multisystem inflammatory syndrome in children (MIS-C) and long-COVID.

In addition, vaccination can also reduce transmission to other individuals (regardless of age) and, by alleviating community transmission, may aid in reducing the need for non-pharmaceutical interventions – especially school closures, quarantines and lockdowns.


Previous data have suggested that an inactivated SARS-CoV-2 vaccine (also known as CoronaVac) is safe and immunogenic for children, and induced well-documented humoral responses in this age group (i.e., up to 17 years of age).

https://www.news-medical.net/news/202202...ldren.aspx

[Levin]

Umm, maybe for children, they should use this type of vaccine since quite a few countries did not approve mRNA vaccines for children due to children's more active immune systems.

[Teeth53]

Umm, maybe for children, they should use this type of vaccine since quite a few countries did not approve mRNA vaccines for children due to children's more active immune systems.

You........

[Teeth53]

The study was conducted in Chile between June 27, 2021, and January 12, 2022. 

The authors have used a large prospective national cohort that included approximately two million children and adolescents.

More specifically, for children and adolescents that underwent a full primary immunization with CoronaVac, the adjusted vaccine effectiveness was 74.5%, 91.0%, and 93.8% for COVID-19 development, hospitalization, and ICU admission, respectively.

Literature shows certain benefits, as vaccination can prevent severe COVID-19 cases and potential deaths among children with underlying health conditions. 

Furthermore, the vaccination may prevent long-term consequences of SARS-CoV-2 infection, including multisystem inflammatory syndrome in children (MIS-C) and long-COVID.

In addition, vaccination can also reduce transmission to other individuals (regardless of age) and, by alleviating community transmission, may aid in reducing the need for non-pharmaceutical interventions – especially school closures, quarantines and lockdowns.


Previous data have suggested that an inactivated SARS-CoV-2 vaccine (also known as CoronaVac) is safe and immunogenic for children, and induced well-documented humoral responses in this age group (i.e., up to 17 years of age).

https://www.news-medical.net/news/202202...ldren.aspx

A recent study on vaccine effectiveness showed that a complete primary immunization with CoronaVac effectively protects against severe coronavirus disease 2019 (COVID-19) for children and adolescents between 6 and 16 years of age